Siegel RL, Miller KD, Wagle NSJemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17–48. https://doi.org/10.3322/caac.21763

Article  PubMed  Google Scholar 

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660

Article  CAS  PubMed  Google Scholar 

Dee EC, Nezolosky MD, Chipidza FE, Arega MA, Butler SS, Sha ST et al (2020) Prostate cancer-specific mortality burden by risk group among men with localized disease: implications for research and clinical trial priorities. Prostate 80:1128–1133. https://doi.org/10.1002/pros.24041

Article  PubMed  Google Scholar 

Wenzel M, Wurnschimmel C, Ruvolo CC, Nocera L, Tian Z, Saad F et al (2021) Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores. Prostate 81:874–881. https://doi.org/10.1002/pros.24184

Article  PubMed  Google Scholar 

Rider JR, Sandin F, Andrén O, Wiklund P, Hugosson JStattin P (2013) Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. Eur Urol 63:88–96. https://doi.org/10.1016/j.eururo.2012.08.001

Article  PubMed  Google Scholar 

Chang AJ, Autio KA, Roach M, 3rdScher HI (2014) High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol 11:308–323. https://doi.org/10.1038/nrclinonc.2014.68

Mano R, Eastham JYossepowitch O (2016) The very-high-risk prostate cancer: a contemporary update. Prostate Cancer Prostatic Dis 19:340–348. https://doi.org/10.1038/pcan.2016.40

Article  CAS  PubMed  PubMed Central  Google Scholar 

National Comprehensive Cancer Network (NCCN) (2023) NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 1. http://www.nccn.org

Boyle HJ, Alibhai S, Decoster L, Efstathiou E, Fizazi K, Mottet N et al (2019) Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. Eur J Cancer 116:116–136. https://doi.org/10.1016/j.ejca.2019.04.031

Article  CAS  PubMed  Google Scholar 

EAU Guidelines Office (2024) EAU Guidelines. Presented at the EAU Annual Congress, Paris, ISBN 978-94-92671-23-3. https://uroweb.org/guidelines

Kishan AU, Sun Y, Hartman H, Pisansky TM, Bolla M, Neven A et al (2022) Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. Lancet Oncol 23:304–316. https://doi.org/10.1016/s1470-2045(21)00705-1

Article  CAS  PubMed  Google Scholar 

Chi KN, Chowdhury S, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R et al (2021) Apalutamide in patients with metastatic castration-sensitive prostate Cancer: final survival analysis of the Randomized, Double-Blind, phase III TITAN Study. J Clin Oncol 39:2294–2303. https://doi.org/10.1200/jco.20.03488

Article  CAS  PubMed  Google Scholar 

Gu W, Han W, Luo H, Zhou F, He D, Ma L et al (2022) Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial. Lancet Oncol 23:1249–1260. https://doi.org/10.1016/s1470-2045(22)00507-1

Article  CAS  PubMed  Google Scholar 

Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN et al (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16:152–160. https://doi.org/10.1016/s1470-2045(14)71205-7

Article  CAS  PubMed  Google Scholar 

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS et al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424–433. https://doi.org/10.1056/NEJMoa1405095

Article  CAS  PubMed  PubMed Central  Google Scholar 

Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED et al (2022) Darolutamide and Survival in Metastatic, hormone-sensitive prostate Cancer. N Engl J Med 386:1132–1142. https://doi.org/10.1056/NEJMoa2119115

Article  CAS  PubMed  PubMed Central  Google Scholar 

Halabi S, Jiang S, Terasawa E, Garcia-Horton V, Ayyagari R, Waldeck AR et al (2021) Indirect comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-resistant prostate Cancer. J Urol 206:298–307. https://doi.org/10.1097/ju.0000000000001767

Article  PubMed  Google Scholar 

Liu M, Hong Y, Duan X, Zhou Q, Chen J, Liu S et al (2024) Unveiling the metal mutation nexus: exploring the genomic impacts of heavy metal exposure in lung adenocarcinoma and colorectal cancer. J Hazard Mater 461:132590. https://doi.org/10.1016/j.jhazmat.2023.132590

Article  CAS  PubMed  Google Scholar 

Chen H, Wang B, Zhang Y, Shu Y, Dong H, Zhao Q et al (2023) A unified DNA- and RNA-based NGS strategy for the analysis of multiple types of variants at the dual nucleic acid level in solid tumors. J Clin Lab Anal 37:e24977. https://doi.org/10.1002/jcla.24977

Article  CAS  PubMed  PubMed Central  Google Scholar 

Devos G, Tosco L, Baldewijns M, Gevaert T, Goffin K, Petit V et al (2023) ARNEO: a randomized phase II trial of Neoadjuvant Degarelix with or without Apalutamide Prior to Radical Prostatectomy for High-risk prostate Cancer. Eur Urol 83:508–518. https://doi.org/10.1016/j.eururo.2022.09.009

Article  CAS  PubMed  Google Scholar 

McKay RR, Xie W, Ye H, Fennessy FM, Zhang Z, Lis R et al (2021) Results of a Randomized phase II trial of intense androgen deprivation therapy prior to Radical Prostatectomy in men with High-Risk localized prostate Cancer. J Urol 206:80–87. https://doi.org/10.1097/ju.0000000000001702

Article  PubMed  PubMed Central  Google Scholar 

Moltzahn F, Karnes J, Gontero P, Kneitz B, Tombal B, Bader P et al (2015) Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patients. Prostate Cancer Prostatic Dis 18:31–37. https://doi.org/10.1038/pcan.2014.41

Article  CAS  PubMed  Google Scholar 

Wenzel M, Würnschimmel C, Ruvolo CC, Nocera L, Tian Z, Saad F et al (2021) Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores. Prostate 81:874–881. https://doi.org/10.1002/pros.24184

Article  PubMed  Google Scholar 

Montgomery B, Tretiakova MS, Joshua AM, Gleave ME, Fleshner N, Bubley GJ et al (2017) Neoadjuvant Enzalutamide Prior to Prostatectomy. Clin Cancer Res 23:2169–2176. https://doi.org/10.1158/1078-0432.Ccr-16-1357

Article  CAS  PubMed  Google Scholar 

Efstathiou E, Davis JW, Pisters L, Li W, Wen S, McMullin RP et al (2019) Clinical and biological characterisation of Localised High-risk prostate Cancer: results of a Randomised Preoperative Study of a luteinising hormone-releasing hormone agonist with or without Abiraterone acetate plus Prednisone. Eur Urol 76:418–424. https://doi.org/10.1016/j.eururo.2019.05.010

Article  CAS  PubMed  PubMed Central  Google Scholar 

McKay RR, Berchuck J, Kwak L, Xie W, Silver R, Bubley GJ et al (2021) Outcomes of post-neoadjuvant intense hormone therapy and surgery for high risk localized prostate Cancer: results of a pooled analysis of contemporary clinical trials. J Urol 205:1689–1697. https://doi.org/10.1097/ju.0000000000001632

Article  PubMed  Google Scholar 

McKay RR, Montgomery B, Xie W, Zhang Z, Bubley GJ, Lin DW et al (2018) Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. Prostate Cancer Prostatic Dis 21:364–372. https://doi.org/10.1038/s41391-017-0009-6

Article  PubMed  Google Scholar 

Zhuang J, Wang Y, Zhang S, Fu Y, Huang H, Lyu X et al (2023) Androgen deprivation therapy plus abiraterone or docetaxel as neoadjuvant therapy for very-high-risk prostate cancer: a pooled analysis of two phase II trials. Front Pharmacol 14:1217303. https://doi.org/10.3389/fphar.2023.1217303

Article  CAS  PubMed  PubMed Central  Google Scholar 

Herberts C, Annala M, Sipola J, Ng SWS, Chen XE, Nurminen A et al (2022) Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. Nature 608:199–208. https://doi.org/10.1038/s41586-022-04975-9

Article  CAS  PubMed